Currentsierra health and lifePolicy 2026T0072FF

Visual Information Processing Evaluation and Orthoptic and Vision Therapy

Policy governing coverage and medical necessity for visual information processing evaluations, orthoptic therapy (vision therapy), occlusion and pharmacologic penalization for amblyopia, and prism adaptation for strabismus for UnitedHealthcare Commercial and Individual Exchange plans.

Policy Summary

Payersierra health and life

PolicyVisual Information Processing Evaluation and Orthoptic and Vision Therapy

Policy CodePolicy 2026T0072FF

Change TypeTemplate update and archival of prior versions

Effective DateJan 1, 2026

Next Review Date

Key ActionVerify member-specific benefits and obtain prior authorization or benefit verification as required before requesting vision therapy or device-based digital therapeutics.

SourceLink

POLICY UPDATE CHANGES

Created shared policy version to support application to Oxford plan membership and archived previous policy versions.

3Proven therapy types

5Unproven / not medically necessary

6-12 wksTypical trial durations

12 RCTsCITT evidence

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

VRT/NES evidence level

01/01/2026Policy history date

Coverage Criteria and Medical Necessity

Evidence summaries and applicability

Evidence summaries and applicability — overarching evidence findings that affect coverage decisions:

Evidence summary

High-quality randomized trials and meta-analyses support office-based vergence/accommodative therapy with home reinforcement as effective for improving clinical motor signs (NPC, PFV) in children with symptomatic convergence insufficiency; evidence for symptom relief is mixed.
Primary sources: Scheiman et al. 2020 (Cochrane NMA), CITT/CITT-ART trials, Morrison et al. 2024.
For amblyopia, multiple RCTs and network meta-analyses demonstrate that established treatments (refractive correction, patching/occlusion, and pharmacologic penalization with atropine) are effective; adjunctive approaches (binocular/dichoptic therapies, perceptual learning, digital therapeutics) show promising but variable results and generally require more high-quality and longer-term comparative data to establish equivalence or superiority to standard care.
Primary sources: Li et al. 2020 NMA; PEDIG trials; recent RCTs and systematic reviews (Tsani et al.; Xiao et al.; Kadhum et al.; Wygnanski-Jaffe et al.).
Prism Adaptation Therapy (PAT) has demonstrated diagnostic and prognostic value and can improve surgical planning and outcomes for certain forms of acquired esotropia; prism wear may benefit selected patients but long-term complete weaning rates and outcomes are variable across cohorts.
Primary sources: PAS multicenter RCT, observational studies (Crouch et al., Choe et al.).
Evidence for remote, online, home-based, or purely digital vision therapies is evolving: some RCTs and device-specific trials (e.g., CureSight, Luminopia One, dichoptic games/movies) report clinically meaningful short-term VA improvements and noninferiority to patching in select populations, but many studies have limitations including short follow-up, adherence issues, heterogeneous interventions, and inconsistent comparative results versus standard treatments.
Primary sources: Wygnanski-Jaffe et al. pivotal trial; Xiao et al.; Jost et al.; RCTs summarized in systematic reviews (Roda 2024; Tsani 2024).
For post-stroke visual field defects and other neuro-ophthalmic injuries, the evidence is limited and of mixed quality: some RCTs of perceptual-learning or VR-based digital therapeutics report improvements in visual field measures in adherent participants, but systematic reviews (Cochrane Pollock et al.) highlight heterogeneity, low certainty, and inconsistent functional benefits in activities of daily living.
Primary sources: Namgung et al. 2024/2025 RCTs; Pollock 2019 Cochrane review.
Vision restoration therapies (VRT), non-invasive electrical stimulation (NES), and many visual perceptual or restitutive interventions have conflicting or low-quality evidence; improvements on technical vision measures have been reported but clinical relevance, durability, and generalizability are uncertain.
Primary sources: Navarro et al. 2023 (NES), Park et al. 2024 review, RevitalVision evidence reviews.
Clinical practice guidelines converge on core, evidence-backed treatments: refractive correction, patching/occlusion, and pharmacologic penalization for amblyopia; office-based VT for convergence insufficiency is endorsed where evidence supports improved motor outcomes; guidelines generally note insufficient evidence to recommend VT for learning disabilities or as routine therapy for many other indications.
Primary sources: AAO, AAP/AAPOS/AACO joint statement, NICE stroke guidance, VA/DoD mild TBI guidance.

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Benefit verification / potential prior authorization

Verify member benefits and exclusions before providing Vision Therapy or device-based digital therapeutics. Coverage is member-specific and governed by the member benefit plan document and applicable mandates; inclusion of a procedure code in this policy does not guarantee coverage.

Reference member-specific benefit document and federal/state mandates.
Confirm Vision Therapy (orthoptic training) exclusion if present in plan.

Prior Authorization

Prior authorization for digital/binocular devices

Prior authorization is recommended for digital/binocular device therapies (including eye‑tracking systems and dichoptic/digital therapeutics) when requested. Submit documentation showing prior conservative therapies, trial evidence (noninferiority or comparative trials vs. patching/standard of care), and intended treatment parameters.

Provide RCT evidence summary when available (e.g., CureSight noninferiority trial, Xiao et al. dichoptic RCT).

Procedure and Billing Codes

Applicable procedure codes listedmixed

0687T	Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session.
0688T	Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month.
0704T	Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment.
0705T	Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days.
0706T	Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month.
92065	Orthoptic training; performed by a physician or other qualified health care professional.
92066	Orthoptic training; under supervision of a physician or other qualified health care professional.
92499	Unlisted ophthalmological service or procedure

Billing Rule

Include applicable procedure codes on claims and verify member exclusions

Inclusion of CPT/HCPCS procedure codes in this policy is for reference only; listing does not guarantee coverage — verify member benefits and submit supporting documentation when billing.

Ensure claims include the appropriate codes (e.g., 0687T–0688T, 0704T–0706T, 92065, 92066, 92499) and medical necessity documentation when required.
Attach prior authorization approvals or clinical rationale if coverage is uncertain.

Clinical Background and Evidence Overview

Amblyopia arises from abnormal visual development in infancy and childhood due to inadequate stimulation of visual pathways. Timely identification and treatment (refractive correction, occlusion/patching, or pharmacologic penalization) can improve visual acuity and reduce long-term disability risk. Convergence insufficiency is characterized by inability to maintain binocular function at near, and orthoptic/vision therapy aims to improve vergence and accommodative control through supervised training.

The body of evidence includes both well-proven therapies (eg, refractive correction, patching, atropine for amblyopia; office-based vergence therapy for pediatric CI) and many unproven or low-quality interventions (eg, many digital/home-only programs, visual-perceptual training for learning disabilities). Clinical recommendations in the policy reflect this distinction and emphasize established first-line treatments while reserving experimental or device-specific approaches for situations with appropriate supporting evidence.

FDA clearance of a device or software product (for example, De Novo or 510(k) actions) is distinct from payer coverage determinations. Vision therapy itself is not subject to FDA regulation, and device clearance does not automatically imply that the therapy or device will be covered; coverage decisions require assessment of the clinical evidence and member plan terms.

For post-stroke visual field rehabilitation and routine prism use, the evidence remains limited and inconsistent: Cochrane reviews reported insufficient evidence for restitutive approaches and low-quality findings for prisms or scanning training, and prism-adaptation studies show mixed utility for surgical planning rather than clear rehabilitative benefit. These gaps limit recommendations for routine reimbursement without stronger supporting data.

Definitions and Measurement Terms

inv-61: Amblyopia — definition and clinical context

PathophysiologyOccurs when the brain receives a poor image from one eye during early years, preventing normal visual pathway development and resulting in reduced visual acuity (lazy eye).

Typical age of onsetDevelops during infancy and early childhood when visual system maturation occurs.

Clinical relevanceIdentified amblyopia or amblyopia risk factors (eg, high refractive error, anisometropia) should prompt timely evaluation and treatment to improve visual outcomes.

Related conditionsOften associated with strabismus (esotropia/exotropia) or significant refractive error; requires refractive correction as part of management.

inv-62: Occlusion Therapy — definition of patching

Definition

Policy History and Revisions

2026-01-01template_update_and_archivalLatest

Template updated and a shared policy version created to support application to Oxford plan membership; prior policy versions (2025T0072EE and VISION 011.31) were archived.

This policy version includes a template update and archival of prior versions. The revision recorded on 01/01/2026 is not material to clinical coverage criteria and is noted in the policy history for reference.

Policy Summary

Payersierra health and life

PolicyVisual Information Processing Evaluation and Orthoptic and Vision Therapy

Policy CodePolicy 2026T0072FF

Change TypeTemplate update and archival of prior versions

Effective DateJan 1, 2026

Next Review Date

Key ActionVerify member-specific benefits and obtain prior authorization or benefit verification as required before requesting vision therapy or device-based digital therapeutics.

SourceLink

On This Page

Document prior refractive correction, patching or atropine attempts and adherence.

Include device identification (manufacturer, model) and FDA status if applicable.

Note

Prior authorization not specified in policy

Some services in this policy do not specify explicit prior authorization codes or utilization rules. Providers must still verify member benefits and follow plan-specific PA procedures.

Absence of a PA code in this policy does not imply PA is not required by the member's plan.
Contact payer to confirm operational PA requirements and submission process.

Prior Authorization

Prior authorization for PAT / prism therapy

Prior authorization is recommended for Prism Adaptation Therapy (PAT) and prolonged prism‑glass wear when used diagnostically or therapeutically for esotropia. Provide detailed clinical documentation of deviation magnitude, changes with PA, and prior treatments to support medical necessity.

Document angle of deviation (PD), response to prism adaptation testing (PA), and whether PA is being used as a prognostic test for augmented surgical dosing.
Include history of refractive correction, prior occlusion or other therapies, and duration of prism wear.
Note that PAT may change surgical planning and has evidence supporting improved surgical outcomes in PA responders.

Prior Authorization

Prior authorization recommended for exotropia / esotropia interventions

Prior authorization is recommended for interventions for clinically significant exotropia or esotropia (surgical or device-based) that are expected to change alignment or function. Conservative-first management is generally expected prior to surgical escalation.

Document prior conservative therapies (refractive correction, occlusion, prism, orthoptic exercises) and objective measures (angle, NCS, stereoacuity).
For intermittent exotropia, conservative options and observation may be reasonable — document rationale for surgery or advanced device interventions.
Include preoperative assessments and expected functional improvement.

Prior Authorization

Prior authorization recommended for VRT / NES

Prior authorization is recommended for Vision Restoration Therapy (VRT) and Non‑Invasive Electrical Stimulation (NES) for visual field defects (e.g., post‑stroke) because evidence is limited and results are variable; require clear diagnostic data and prior conservative management.

Provide baseline and planned outcome measures (Humphrey visual fields, mean sensitivity, documented defect area).
Document prior rehabilitation efforts and functional impact on activities of daily living.
Note that insufficient or low‑quality evidence may support a denial or medical‑necessity review.

Prior Authorization

Prior authorization for device‑based digital therapeutics

When requesting coverage for FDA‑cleared device‑based digital therapeutics (e.g., Luminopia One, CureSight), include the device name, FDA decision/clearance, indication, prescribed treatment parameters, and adherence monitoring plan.

Attach device-specific evidence (pivotal trial summaries, noninferiority data) and patient age/indication consistent with clearance.
Specify duration, daily dose (minutes/hours), total planned hours, and how adherence will be tracked and reported.
If device is prescribed off‑label, provide supporting evidence and rationale.

Note

Coverage dependent on member‑specific benefits

Coverage decisions depend on the member‑specific benefit plan. Always reference and reconcile the member's benefit document; the policy is informational and does not replace plan terms.

In event of conflict, the member-specific benefit plan governs.
Confirm any state or federal mandates that might affect coverage.

Denial Risk

Evidence limitations for remote / digital VT

Evidence for remote, online, and digital vision therapy is heterogeneous and of limited quality in many areas. Be prepared for medical‑necessity review or denial when high‑quality comparative evidence (long‑term, randomized, sham‑controlled) is lacking.

Highlight adherence data and long‑term outcomes when available to strengthen the request.
Document limitations of existing trials (small size, short follow‑up, single‑arm designs) in the submission.

Step Therapy

Step therapy expectations / not specified

There is no explicit step‑therapy program detailed in this policy; however, standard practice and guidelines expect conservative measures (refractive correction, occlusion/atropine) before escalation.

Document trials of refractive correction and occlusion/atropine prior to requesting higher‑intensity or device‑based therapies for amblyopia.
If step‑therapy is required by the member's plan, follow plan procedures and document failures or intolerance to first‑line measures.

Denial Risk

Lack of evidence of prism adaptation (PA) and denial risk

Lack of high‑quality evidence for prism adaptation or other interventions in some subgroups may lead to denial if diagnostic criteria, prior conservative therapy, or objective baseline/post‑treatment measures are not provided.

Provide PA response details (magnitude change, stability) and prognostic implications for surgical planning.
Include long‑term follow‑up data when available to support continued coverage.

Denial Risk

Insufficient evidence / documentation may trigger denial

Insufficient clinical documentation, absent objective baseline testing, or missing evidence of prior conservative therapy increases the likelihood of medical‑necessity review or denial for many VT and device requests.

Include baseline measures (VA, stereoacuity, NPC, PFV, Humphrey visual fields where applicable).
Attach prior treatment records and adherence information.

Denial Risk

Noncompliance risk

Noncompliance with prescribed conservative treatments (e.g., occlusion/patching) is a common reason for treatment failure and may affect coverage decisions for escalation to device‑based or surgical therapies. Document adherence and reasons for nonadherence.

Provide objective adherence data when available (device logs, clinic notes).
If nonadherence limits benefit of first‑line therapy, document barriers and steps taken to improve compliance.

Documentation Required

Required clinical outcome documentation

Required clinical outcome documentation for prior authorization or medical‑necessity review should include objective baseline and post‑treatment measures relevant to the intervention (e.g., amblyopic‑eye VA, stereoacuity, NPC, PFV, Humphrey visual fields, validated symptom scores like CISS).

For amblyopia: report best‑corrected visual acuity (logMAR), prior refractive correction, patching/atropine history, and adherence.
For convergence and vergence therapy: report NPC, PFV, and CISS baseline and follow‑up.
For VRT/VFD interventions: include Humphrey visual field mean sensitivity, defect area, and objective detection measures.
For prism/PAT: include angle measurements (PD), PA response, and diplopia questionnaires.

Documentation Required

Clinical documentation elements to include

Clinical documentation should include the indication, prior treatments attempted (with durations and adherence), objective baseline testing, planned treatment parameters, and measurable outcomes to be used for assessing benefit.

Specify diagnosis, age, severity, and functional impact.
List prior conservative therapies (refractive correction, occlusion, atropine, prisms) and documented response.
For devices: include model, FDA clearing/labeling, prescribed protocol, and monitoring plan.

Documentation Required

Required clinical documentation elements (prism / strabismus)

Required documentation elements for prism/strabismus interventions and prism adaptation include type and magnitude of deviation, response to PA, prior treatments, corrective lens status, and validated diplopia outcome measures.

Record near and distance deviations in prism diopters, PA‑revealed latent deviation, and stability over time.
Include sensory testing results (Worth 4‑dot, stereoacuity) and diplopia questionnaire scores.

Documentation Required

Required outcome documentation (VRT / visual field)

Required outcome documentation for VRT and visual field therapies should include baseline and post‑therapy Humphrey visual fields, mean sensitivity changes, area of improved field (degrees²), and objective detection measures. Report adherence and follow‑up duration.

Provide Humphrey 24‑2 or appropriate program outputs and quantified sensitivity changes (dB).
Report functional outcomes (ADLs, reading ability) when available.

Documentation Required

Device therapy documentation

When prescribing device therapies, document device identification, FDA status, prescribed settings (daily dose, total hours), adherence monitoring, and any technical support arrangements.

Include device regulatory information (De Novo, 510(k), clearance date) and indication per labeling.
Provide plan for data download or report frequency (e.g., per calendar month billing codes 0688T/0706T).

Billing Rule

Reference member‑specific plan

Always reference the member‑specific plan when making coverage decisions; this policy provides interpretive guidance but the member contract governs and may impose additional PA, step therapy, or exclusion rules.

If the member plan excludes Vision Therapy, deny or route per exclusion language.
Confirm whether Medicare NCD/LCDs or state mandates apply for the member.

Occlusion (patching) therapy involves patching the unaffected (better) eye to provide monocular stimulation to the amblyopic eye, promoting visual development (AAPOS, 2021).

PurposeTo force use of the amblyopic eye and improve amblyopic-eye visual acuity as part of standard amblyopia treatment.

Typical prescriptionUsed as part of a regimen that may vary by age and severity (eg, part-time vs full-time patching) and is often combined with refractive correction.

Alternative pharmacologic optionPharmacologic penalization (eg, atropine) is an established alternative to occlusion for penalizing the better-seeing eye.

LimitationsPatching improves acuity but does not necessarily correct associated strabismus; adherence is a key determinant of success.

inv-63: Orthoptic Therapy / Vision Therapy — definition and typical delivery

DefinitionOrthoptic Therapy (Vision Therapy) is a program of supervised in-office exercises with home reinforcement, performed over weeks to months to improve binocular function, oculomotor control, accommodation, and vergence responses (AAPOS, 2020).

Delivery modelTypically includes regular office-based sessions taught by orthoptists or optometrists, plus prescribed at-home exercises to reinforce training.

Therapeutic componentsMay use lenses, prisms, filters, patches, electronic targets, or balance boards alongside exercises.

IndicationsUsed for non-strabismic binocular disorders, ocular motility dysfunctions, accommodative disorders, and as adjunctive treatment for amblyopia per professional guidance.

Evidence noteHome-based VT alone may be less effective than office-based VT with home reinforcement; preferred management involves therapist-supervised sessions when possible.

inv-64: Prism Adaptation Therapy — definition and purpose

DefinitionPrism Adaptation Therapy (PAT) uses prisms to align the visual axes and simulate absence of strabismus, helping determine the ‘true’ angle of deviation and guide surgical targets (AAO 2018).

Diagnostic rolePAT measures changes in ocular deviation when prisms are worn to reveal latent or dose-relevant angle changes useful for preoperative planning.

Therapeutic/planning utilityResponses to PAT can identify patients who may benefit from augmented surgical dosing and reduce undercorrection risk.

Dose-relevant change exampleStudies reported clinically relevant angle changes during PAT (eg, ≥3 prism diopters in 82% of decEPH patients).

inv-65: Vision Restoration Therapy (VRT) — definition and intent

DefinitionVision Restoration Therapy (VRT) is an in-home computer-based program intended to strengthen residual visual processing of surviving neuronal structures after neurologic injury (eg, stroke, trauma) through repetitive stimulation/training.

IntentAims to improve detection sensitivity and expand functional visual field by training residual or border visual areas over days to weeks.

Typical deliveryUsually delivered at home with repeated sessions over weeks to months; study protocols vary in frequency and duration.

Evidence summaryClinical evidence is limited and conflicting with significant study design limitations; benefits remain uncertain and require larger rigorous trials.

inv-66: Near Point of Convergence (NPC) — clinical measure definition

DefinitionNear Point of Convergence (NPC) is the closest point at which the eyes can maintain binocular single vision when converging on a near target; used to assess convergence function in CI.

Clinical useMeasured clinically to assess response to vergence/accommodative therapy and included in trial success criteria (eg, normal NPC < 6 cm or improvement ≥4 cm).

Outcome reportingNPC change over treatment and at follow-up is used to document motor improvement in CI trials.

inv-67: Positive Fusional Vergence (PFV) — clinical measure definition

DefinitionPositive Fusional Vergence (PFV) quantifies the amplitude of fusional convergence (base-out) that a patient can generate to maintain single binocular vision; used in CI assessment.

Clinical thresholdsTrial success criteria have included normal PFV (eg, passing Sheard's criterion and base-out break > 15Δ) or improvement by ≥10Δ.

Use in outcomesPFV is measured pre- and post-therapy to document objective motor improvement with vergence/accommodative therapy.

inv-68: Convergence Insufficiency Symptom Survey (CISS) — validated symptom score definition

DefinitionConvergence Insufficiency Symptom Survey (CISS) is a validated self-reported symptom questionnaire used to quantify symptoms related to convergence insufficiency.

Role in trialsCISS scores are used as patient-reported outcomes in CI trials but improvement in CISS alone may not suffice to define treatment success.

Score interpretationTrials report mean CISS improvements (eg, mean improvements reported in vergence/accommodative therapy groups), used alongside objective measures (NPC, PFV).

inv-69: Binocular/dichoptic therapy — definition and mechanism

DefinitionBinocular or dichoptic therapy presents different visual input to each eye (eg, via games, movies, or device-based stimuli) to rebalance contrast and promote binocular vision and use of the amblyopic eye.

MechanismBy delivering separate stimuli to each eye, these therapies reduce suppression and encourage binocular integration and stereoacuity improvement.

DeliveryOften delivered with home-based digital devices or supervised programs; some FDA-cleared devices (eg, CureSight, Luminopia One) use dichoptic paradigms.

Evidence noteRandomized trials show mixed results versus patching; device-specific RCT evidence and adherence documentation are important for evaluation.

inv-70: Prism adaptation test (PAT) — definition and role in planning

DefinitionPrism adaptation test (PAT) is a diagnostic procedure that measures how the ocular deviation (angle of squint) changes when prisms are worn, revealing latent or adapted components of strabismus for surgical planning.

Role in planningPAT identifies prism-adapted angles that can guide augmented surgical dosing and may improve surgical success rates when used to plan augmentation.

Clinical impactPAS and other studies reported higher surgical success for PA responders undergoing augmented surgery versus non-PA patients (eg, 89% vs 72% at 6 months).

Dose-relevant changePAT often identifies clinically relevant angle changes (eg, ≥3 prism diopters) that alter surgical targeting.

inv-71: Successful motor outcome — examples of study success definitions

ExamplesSuccessful motor outcome definitions used in studies include residual esotropia ≤ 10 prism diopters after correction (Choe et al.) and postoperative deviation ≤ 8 prism diopters (PAS).

ContextDefinitions of success vary by study and condition; authors often combine motor thresholds with symptom control or sensory fusion metrics.

Use for reportingReport success thresholds (eg, ≤10 PD or ≤8 PD) when documenting outcomes for prism or surgical interventions.

inv-72: Dose-relevant angle change — definition (≥ 3 prism diopters in some studies)

DefinitionDose-relevant angle change: a change in ocular deviation of ≥ 3 prism diopters (PD) was used in some studies to indicate a clinically relevant change during prism adaptation testing.

Clinical significanceSuch angle changes during PAT can alter surgical planning or prism prescription decisions.

Reported frequencyExample: 82% of decEPH patients showed dose-relevant changes ≥3 PD during PAT (Gietzelt et al.).

inv-73: Humphrey visual field (HVF) measures — definition and use as outcome measure

DefinitionHumphrey visual field (HVF) measures refer to automated static perimetry used to quantify visual field sensitivity and area; outcomes include mean sensitivity changes and area (degrees²).

Use as outcomeUsed as standardized objective outcome measures in trials of visual perceptual learning or VRT to document changes in visual field sensitivity or area.

Typical thresholdsClinically meaningful improvements reported in trials include area increases (eg, 74–108 degrees²) or sensitivity improvements (eg, ≥6 dB).

Documentation requirementBaseline and post-therapy HVF testing and adherence data are recommended when evaluating VRT or similar interventions.

inv-74: Newcastle Control Score (NCS) — definition for intermittent distance exotropia control measurement

DefinitionNewcastle Control Score (NCS) is a clinical measure used to quantify control of intermittent distance exotropia in children and in cohort studies reporting treatment outcomes.

UseNCS is used to assess changes in control over time and to compare treated versus untreated cohorts in exotropia studies.

InterpretationImprovement in NCS is considered evidence of better control even when angle deviation is unchanged; surgical groups often show larger NCS improvements than non-surgical treatments.

inv-75: Vision Restoration Therapy (VRT) — definition repeated for clarity

DefinitionVision Restoration Therapy (VRT) is a computer-based repetitive stimulation/training program targeting residual vision or visual field borders to improve detection sensitivity and expand functional visual field.

DeliveryTypically an in-home computerized program delivered daily over weeks to months with variable training schedules used in clinical trials.

Evidence noteClinical evidence is limited and conflicting; reported within-group improvements exist but between-group findings are inconsistent and require larger rigorous trials.

inv-76: Non-invasive Electrical Stimulation (NES) — definition and target

DefinitionNon‑invasive Electrical Stimulation (NES) comprises external stimulation techniques (eg, tDCS) applied to visual pathways or cortex aiming to improve visual function.

TargetsApplied to visual cortex or related pathways to transiently or persistently modulate visual processing, often combined with perceptual training.

Evidence summarySystematic reviews of RCTs (eg, 13 RCTs, 441 individuals) suggest NES may modestly improve visual acuity or QoL in the short term, but clinical relevance is uncertain and adverse effects are more common than sham.

inv-77: Vision therapy (VT) / Orthoptics — clinical definition and aims

DefinitionVision therapy (VT) / Orthoptics comprises active training procedures—often office-based with home reinforcement—aimed at improving fixation, oculomotor control, sensory and motor fusion, accommodation, vergence, and visual information processing.

Clinical aimsIntended to treat strabismus, amblyopia adjunctively, ocular motility disorders, accommodative and vergence dysfunctions, and related deficits in visual processing.

Delivery and componentsPrograms commonly include supervised office sessions, prescribed home exercises, and may use lenses, prisms, electronic targets, and other adjuncts.

Guideline contextProfessional bodies (AOA, AAPOS, AAO) acknowledge VT for several conditions but note stronger evidence for office-based therapy over home-only programs.

inv-78: Amblyopia risk factors

Risk factorsHigh levels of refractive error and anisometropia identified on preschool screening increase the likelihood of developing amblyopia and are considered amblyopia risk factors.

Screening relevancePreschool vision screening that detects these risk factors should prompt refractive correction and close follow-up to prevent amblyopia.

Associated findingsStrabismus and significant uncorrected refractive error commonly coexist with amblyopia risk and warrant evaluation and management.

Guideline basisProfessional society guidance (AAPOS, AAO) recognizes these factors as medical conditions meriting intervention.